|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
National Cancer Institute: SEER Stat fact
sheets: Lung and bronchus cancer. http://seer.cancer.gov/statfacts/html/lungb.html.
Accessed August 12, 2013.
|
|
3.
|
Furuse K, Fukuoka M, Kawahara M, et al:
Phase III study of concurrent versus sequential thoracic
radiotherapy in combination with mitomycin, vindesine, and
cisplatin in unresectable stage III non-small-cell lung cancer. J
Clin Oncol. 17:2692–2699. 1999.PubMed/NCBI
|
|
4.
|
Curran WJ Jr, Paulus R, Langer CJ, et al:
Sequential vs. concurrent chemoradiation for stage III non-small
cell lung cancer: randomized phase III trial RTOG 9410. J Natl
Cancer Inst. 103:1452–1460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Dillman RO, Herndon J, Seagren SL, Eaton
WL Jr and Green MR: Improved survival in stage III non-small-cell
lung cancer: seven-year follow-up of cancer and leukemia group B
(CALGB) 8433 trial. J Natl Cancer Inst. 88:1210–1215.
1996.PubMed/NCBI
|
|
6.
|
Sause W, Kolesar P, Taylor S IV, et al:
Final results of phase III trial in regionally advanced
unresectable non-small cell lung cancer: Radiation Therapy Oncology
Group, Eastern Cooperative Oncology Group, and Southwest Oncology
Group. Chest. 117:358–364. 2000. View Article : Google Scholar
|
|
7.
|
Edelman MJ, Tang M, Gardner JF, Mullins
CD, Seal B and Davidoff AJ: Therapy (Tx) of locally advanced (LA)
NSCLC in the elderly: Analysis of 6,325 patients from surveillance,
epidemiology and end results (SEER)-Medicare. J Clin Oncol.
26(Suppl 15): 75492008.
|
|
8.
|
Atagi S, Kawahara M, Yokoyama A, et al
Japan Clinical Oncology Group Lung Cancer Study Group: Thoracic
radiotherapy with or without daily low-dose carboplatin in elderly
patients with non-small-cell lung cancer: a randomised, controlled,
phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
Lancet Oncol. 13:671–678. 2012. View Article : Google Scholar
|
|
9.
|
Yamamoto N, Nakagawa K, Nishimura Y, et
al: Phase III study comparing second- and third-generation regimens
with concurrent thoracic radiotherapy in patients with unresectable
stage III non-small-cell lung cancer: West Japan Thoracic Oncology
Group WJTOG0105. J Clin Oncol. 28:3739–3745. 2010. View Article : Google Scholar
|
|
10.
|
Goldstraw P, Crowley J, Chansky K, et al
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar
|
|
11.
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
13.
|
National Cancer Institute: Common Toxicity
Criteria (NCI-CTC) version 4.0.3. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Accessed August 13, 2013.
|
|
14.
|
National Comprehensive Cancer Network:
Clinical practice guidelines in oncology: non-small cell lung
cancer, NCCN guidelines version 2 (2013). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Accessed August 13, 2013.
|
|
15.
|
Hutchins LF, Unger JM, Crowley JJ, Coltman
CA Jr and Albain KS: Underrepresentation of patients 65 years of
age or older in cancer-treatment trials. N Engl J Med.
341:2061–2067. 1999.PubMed/NCBI
|
|
16.
|
De Ruysscher D, Botterweck A, Dirx M, et
al: Eligibility for concurrent chemotherapy and radiotherapy of
locally advanced lung cancer patients: a prospective,
population-based study. Ann Oncol. 20:98–102. 2009.PubMed/NCBI
|
|
17.
|
Socinski MA, Zhang C, Herndon JE II, et
al: Combined modality trials of the Cancer and Leukemia Group B in
stage III non-small-cell lung cancer: analysis of factors
influencing survival and toxicity. Ann Oncol. 15:1033–1041. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Rocha Lima CM, Herndon JE II, Kosty M,
Clamon G and Green MR: Therapy choices among older patients with
lung carcinoma: an evaluation of two trials of the Cancer and
Leukemia Group B. Cancer. 94:181–187. 2002.PubMed/NCBI
|
|
19.
|
Langer CJ, Hsu C, Curran WJ, et al:
Elderly patients (pts) with locally advanced non-small cell lung
cancer (LA-NSCLC) benefit from combined modality therapy: Secondary
analysis of radiation therapy oncology group (RTOG) 94-10. In:
Proceedings of the Annual Meeting of the American Society for
Clinical Oncology 21 (abstract 1193); pp. 299a2002
|
|
20.
|
Schild SE, Stella PJ, Geyer SM, et al: The
outcome of combined-modality therapy for stage III non-small-cell
lung cancer in the elderly. J Clin Oncol. 21:3201–3206. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Jalal SI, Riggs HD, Melnyk A, et al:
Updated survival and outcomes for older adults with inoperable
stage III non-small-cell lung cancer treated with cisplatin,
etoposide, and concurrent chest radiation with or without
consolidation docetaxel: analysis of a phase III trial from the
Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol.
23:1730–1738. 2012.
|
|
22.
|
Sgroi MM, Neubauer M, Ansari R, et al: An
analysis of elderly patients (pts) treated on a phase III trial of
cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT)
followed by docetaxel (D) vs observation (O) in pts with stage III
non small cell lung cancer (NSCLC). J Clin Oncol. 25(Suppl 18):
90372007.
|
|
23.
|
Aupérin A, Le Péchoux C, Pignon JP, et al:
Meta-Analysis of Cisplatin/carboplatin based Concomitant
Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group:
Concomitant radio-chemotherapy based on platin compounds in
patients with locally advanced non-small cell lung cancer (NSCLC):
a meta-analysis of individual data from 1764 patients. Ann Oncol.
17:473–483. 2006.
|
|
24.
|
Montazeri A, Milroy R, Hole D, McEwen J
and Gillis CR: Quality of life in lung cancer patients: as an
important prognostic factor. Lung Cancer. 31:233–240. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Langendijk H, Aaronson NK, de Jong JM, ten
Velde GP, Muller MJ and Wouters M: The prognostic impact of quality
of life assessed with the EORTC QLQ-C30 in inoperable non-small
cell lung carcinoma treated with radiotherapy. Radiother Oncol.
55:19–25. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Efficace F, Bottomley A, Smit EF, et al:
Is a patient’s self-reported health-related quality of life a
prognostic factor for survival in non-small-cell lung cancer
patients? A multivariate analysis of prognostic factors of EORTC
study 08975. Ann Oncol. 17:1698–1704. 2006.
|
|
27.
|
Maione P, Perrone F, Gallo C, et al:
Pretreatment quality of life and functional status assessment
significantly predict survival of elderly patients with advanced
non-small-cell lung cancer receiving chemotherapy: a prognostic
analysis of the multi-center Italian lung cancer in the elderly
study. J Clin Oncol. 23:6865–6872. 2005.
|
|
28.
|
Herndon JE II, Fleishman S, Kornblith AB,
Kosty M, Green MR and Holland J: Is quality of life predictive of
the survival of patients with advanced nonsmall cell lung
carcinoma? Cancer. 85:333–340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Brown J, Thorpe H, Napp V, et al:
Assessment of quality of life in the supportive care setting of the
big lung trial in non-small-cell lung cancer. J Clin Oncol.
23:7417–7427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ganz PA, Lee JJ and Siau J: Quality of
life assessment. An independent prognostic variable for survival in
lung cancer. Cancer. 67:3131–3135. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Eton DT, Fairclough DL, Cella D, Yount SE,
Bonomi P and Johnson DH; Eastern Cooperative Oncology Group: Early
change in patient-reported health during lung cancer chemotherapy
predicts clinical outcomes beyond those predicted by baseline
report: results from Eastern Cooperative Oncology Group Study 5592.
J Clin Oncol. 21:1536–1543. 2003. View Article : Google Scholar
|
|
32.
|
Movsas B, Scott C, Langer C, et al:
Randomized trial of amifostine in locally advanced non-small-cell
lung cancer patients receiving chemotherapy and hyperfractionated
radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin
Oncol. 23:2145–2154. 2005. View Article : Google Scholar
|
